Trevi Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing Haduvio (oral nalbuphine ER) to help patients suffering from chronic cough conditions, including idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC)
Trevi Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing Haduvio (oral nalbuphine ER) to help patients suffering from chronic cough conditions, including idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).